Business Context and Reporting Period
This Form 8-K Current Report was filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) on October 12, 2018, covering events occurring on October 5, 2018. The company is an emerging growth company incorporated in Nevada, focused on biotechnology. The filing details a material credit agreement, the appointment of a new Executive Chairman, and amendments to equity incentive plans.
Key Financial Metrics and Agreements
The filing does not provide specific revenue, profit, cash flow, or margin data for the period. The primary financial event is the entry into a Multi-Draw Credit Agreement with Emerald Health Sciences Inc. Key terms include:
- Credit Facility: Up to $20,000,000, unsecured.
- Interest Rate: 7% per annum.
- Maturity Date: October 5, 2022.
- Conversion Terms: Emerald may convert advances into common stock at a fixed price of $0.40 per share.
- Warrants: For each advance, the company issues warrants to purchase 50% of the convertible shares at an exercise price of $0.50 per share, exercisable immediately and expiring in five years.
- Use of Proceeds: Operating purposes.
Material Changes and Corporate Actions
Significant corporate governance and compensation changes were announced:
- Board Appointment: Dr. Avtar Dhillon was elected to the Board and appointed Executive Chairman effective October 5, 2018. He will serve on the Finance and Business Development Special Committee, Audit, Compensation, and Nomination committees.
- Executive Compensation: Dr. Dhillon received a one-time option to purchase 1,000,000 shares at $0.305 per share, vesting monthly over one year.
- Director Compensation Policy: The Board amended the policy for non-employee directors to include:
- Annual cash retainer of $40,000.
- Annual option to purchase 100,000 shares.
- Additional retainers for committee service (e.g., $40,000 for the Finance Committee Chair).
- One-time option award of 200,000 shares for new directors.
- Other Directors: Punit Dhillon and Jim Heppell received one-time options to purchase 200,000 shares each at $0.305 per share.
- Equity Plan Amendment: The 2014 Omnibus Incentive Plan was amended to include an "evergreen" provision reserving 10% of issued and outstanding shares for future issuance.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or forward-looking projections regarding revenue or earnings. Management commentary is limited to the strategic intent of using credit proceeds for operating purposes and the value of Dr. Dhillon's experience in building life science companies. Risks associated with the credit agreement include potential dilution of existing shareholders due to the conversion feature and warrant exercises. The company also noted that the credit agreement is unsecured.
Investor Verification Checklist
- Verify the exact amount of the initial draw under the $20 million credit facility, as the filing only states the maximum capacity.
- Confirm the current number of outstanding shares to calculate the potential dilution impact of the 10% evergreen provision and the new warrants/options.
- Review the full text of the Credit Agreement (Exhibit 10.1) for covenants, default provisions, and specific conversion mechanics not detailed in the summary.
- Check subsequent filings for the actual utilization of the credit line and any further equity issuances related to the warrants.
- Clarify the company's current cash position and burn rate to assess the necessity and timing of future draws under the credit facility.